8-K: Upstream Bio Stockholders Re-Elect Directors and Ratify Auditor at 2025 Annual Meeting

Upstream Bio, Inc. announced that its stockholders approved the election of two Class I directors and ratified PricewaterhouseCoopers LLP as its independent auditor for the 2025 fiscal year at the recent Annual Meeting.

Summary

• Upstream Bio, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025.
• As of the record date, April 14, 2025, there were 53,688,703 shares of common stock outstanding and entitled to vote.
• Stockholders approved the election of Erez Chimovits, M.B.A., M.Sc. and Marcella Kuhlman Ruddy, M.D., M.S. as Class I directors, to serve until the 2028 annual meeting.
• Erez Chimovits received 42,089,191 votes For, 241,430 Withheld, and 1,296,674 Broker Non-Votes.
• Marcella Kuhlman Ruddy received 41,993,308 votes For, 337,313 Withheld, and 1,296,674 Broker Non-Votes.
• Stockholders ratified the selection of PricewaterhouseCoopers LLP (PwC) as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The ratification of PwC received 43,600,758 votes For, 996 Against, and 25,541 Abstain.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposed resolutions passed with strong shareholder support, indicating stability and adherence to corporate governance norms. There are no negative surprises or adverse outcomes reported.

Positives

• All proposals recommended by the company's board were approved by stockholders, indicating strong shareholder support for current governance and management.
• The re-election of Class I directors ensures continuity in the company's leadership.
• The ratification of PwC as the independent auditor provides assurance of continued financial oversight and compliance.

Future Outlook

NA

Industry Context

This 8-K filing is a standard corporate governance update, reporting the outcomes of a routine annual stockholder meeting. It does not contain information that directly relates to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors.

Stakeholder Impact

• Shareholders: The approval of director elections and auditor ratification provides continuity in governance and financial oversight, which is generally positive for shareholder confidence.
• Management: The re-election of directors indicates continued confidence in the current leadership structure.

Next Steps

• The elected Class I directors, Erez Chimovits and Marcella Kuhlman Ruddy, will serve until the company's 2028 annual meeting of stockholders.

Key Dates

Keywords

Upstream Bio, UPB, SEC Filing, 8-K, Annual Meeting, Stockholders Meeting, Corporate Governance, Director Election, Auditor Ratification, PricewaterhouseCoopers, Biotechnology, Pharmaceuticals